- Home
- OBIO vs ZNTL Comparison
OBIO vs ZNTL Comparison
Compare OBIO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ZNTL
- Stock Information
- Founded
- OBIO 2017
- ZNTL 2014
- Country
- OBIO United States
- ZNTL United States
- Employees
- OBIO N/A
- ZNTL N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- ZNTL Health Care
- Exchange
- OBIO Nasdaq
- ZNTL Nasdaq
- Market Cap
- OBIO 205.0M
- ZNTL 238.2M
- IPO Year
- OBIO N/A
- ZNTL 2020
- Fundamental
- Price
- OBIO $5.83
- ZNTL $3.12
- Analyst Decision
- OBIO Strong Buy
- ZNTL Buy
- Analyst Count
- OBIO 4
- ZNTL 7
- Target Price
- OBIO $15.75
- ZNTL $10.86
- AVG Volume (30 Days)
- OBIO 44.2K
- ZNTL 1.2M
- Earning Date
- OBIO 11-11-2024
- ZNTL 11-04-2024
- Dividend Yield
- OBIO N/A
- ZNTL N/A
- EPS Growth
- OBIO N/A
- ZNTL N/A
- EPS
- OBIO N/A
- ZNTL N/A
- Revenue
- OBIO $2,079,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- OBIO $7.68
- ZNTL N/A
- Revenue Next Year
- OBIO $110.40
- ZNTL N/A
- P/E Ratio
- OBIO N/A
- ZNTL N/A
- Revenue Growth
- OBIO N/A
- ZNTL N/A
- 52 Week Low
- OBIO $4.22
- ZNTL $2.83
- 52 Week High
- OBIO $11.69
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- OBIO 60.54
- ZNTL 44.34
- Support Level
- OBIO $5.20
- ZNTL $2.92
- Resistance Level
- OBIO $5.99
- ZNTL $3.23
- Average True Range (ATR)
- OBIO 0.38
- ZNTL 0.17
- MACD
- OBIO 0.12
- ZNTL 0.00
- Stochastic Oscillator
- OBIO 87.20
- ZNTL 38.33
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.